Comparative Pharmacology
Head-to-head clinical analysis: ADVIL LIQUI GELS versus MECLOMEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL LIQUI GELS versus MECLOMEN.
ADVIL LIQUI-GELS vs MECLOMEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.
Meclomen (meclofenamate) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This results in anti-inflammatory, analgesic, and antipyretic effects.
200–400 mg orally every 4–6 hours as needed; maximum 1200 mg/day.
50-100 mg orally every 6-8 hours; maximum 400 mg/day.
None Documented
None Documented
1.8 to 2.5 hours. The short half-life supports dosing every 4 to 6 hours for acute pain and fever.
Terminal elimination half-life: 0.8–1.1 hours for meclofenamic acid; 2–4 hours for metabolites. Short half-life requires frequent dosing (e.g., every 6–8 hours) for sustained effect.
Renal excretion of metabolites and conjugates accounts for approximately 90% of an administered dose. Less than 1% is excreted unchanged. Biliary/fecal elimination accounts for about 10%.
Renal (approximately 70% as metabolites, <5% unchanged); fecal/biliary (approximately 30% as metabolites).
Category C
Category C
NSAID
NSAID